Products

Sylaps

Audio and Video Conferencing, Online Collaboration, Screen Sharing on web browser, mobile and desktop

sylaps.com Productivity & Collaboration / Meetings & Note-Takers

AI Benchmark
Monthly visits
70.7K
Down1.8%MoMOct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Meg Wehrlen
@megxwayne· 4,257 followers
Launched
10y ago
2015-11-30 · Est.

Traffic

Monthly visitsData through Oct 2026
Events1 change

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Meet with anyone. Now.

    Nov 30, 2015 · 10y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct66%
  • Organic Search27%
  • Referrals5%
  • Other2%

Countries

  • Italy84%
  • United States8%
  • India8%

Search

Domain authority —Domain registered 2012-08-19

KeywordMonthly volume
sylaps9,070
sylabs170
silaps cam130
sylaps chat120
vai su sylaps100

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2015-11-30

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

  1. Nov 1 · 15d ago

    Adopted technology: Google Tag ManagerFeatures

    —→Google Tag Manager

    At the time: 70.7K visits/mo

Questions & evidence

How much website traffic does Sylaps get?
Vaneform estimates 70.7K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Sylaps and what platforms does it support?
Sylaps is catalogued under Meetings & Note-Takers: Audio and Video Conferencing, Online Collaboration, Screen Sharing on web browser, mobile and desktop. Supported platforms: Mobile App.

Related products in this category

Productivity & Collaboration / Meetings & Note-Takers

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.